Skip to content
Home About Research Team & Gallery Publications Translation News Join & Contact

Harnessing the Immense Clinical Potential of Targeted Intracellular Delivery

Ligand-free dendrimer medicines that find diseased cells on their own, across the blood-brain barrier, for CNS, retinal, and inflammatory diseases.

150+
Peer-Reviewed
Publications
60+
Validated
Disease Models
7
Species Including
Primates
8
Clinical Trials
6 Ph1 · 2 Ph2
$120M+
VC Funding Raised
via Ashvattha Therapeutics
190+
Patents Awarded
& Pending

Where would you like to start?

Disease-Directed Nanomedicine

The Kannan Labs at the Center for Nanomedicine, Johns Hopkins University, is a world-leading group in dendrimer-based therapeutics. Dendrimers possess the highest surface functional density of all nanomaterials, a property that enables them to interact with disease pathology and disease cells in unique, unexpected ways.

We develop scalable, ligand-free, cell-targeted treatments for long-standing challenges: overcoming the blood-brain barrier, non-viral gene and gene-editing delivery, oral obesity treatments, intracellular antibody delivery, systemic retinal treatments, and more.

Two decades of foundational discovery, validated in over 60 models across six species including primates, has translated into multiple successful clinical trials and JHU spin-out companies with over $120 million in venture funding.

See Our Research

Ligand-Free Cell Targeting

Dendrimers find diseased cells without targeting ligands, guided by disease pathology and injury extent alone.

Scalable DDC Platforms

Dendrimer-drug conjugates are modular, scalable, and cleared intact through the kidney with minimal off-target effects.

Clinical Translation

Positive Phase 2 outcomes in COVID-19, wet AMD, and DME, with active programs at two JHU spin-outs.

Unmet Medical Needs

BBB crossing, neuroinflammation, retinal disorders, epilepsy, and TBI, where patients need new options most.

Our Science

Four dendrimer platforms, each built around a delivery problem that conventional drugs cannot solve.

1 / 4

Meet the Lab

Engineers, chemists, clinicians, and biologists working on one problem: getting medicines to the right cells. Click any card for the full profile.

Kannan Rangaramanujam
Kannan Rangaramanujam, PhD

A chemical engineer with a PhD from Caltech, Prof. Kannan has pioneered dendrimer nanomedicine for over 20 years at Johns Hopkins. His group discovered that hydroxyl PAMAM dendrimers selectively target reactive microglia and macrophages in disease, validated in over 60 models across six species including primates. He is an author of more than 190 patents and co-founded Ashvattha and Samata Therapeutics.

View Full Profile →
Sujatha Kannan
Sujatha Kannan, MD
Professor of Anesthesiology & Critical Care Medicine · Co-founder, Ashvattha & Samata Therapeutics
Kunal Parikh
Kunal Parikh, PhD
Co-founder, Samata Therapeutics · CNS Drug Delivery, Cannabinoids & Psychedelics

Research Associates

1 associate
Wathsala Liyanage
Research Associate
Wathsala Liyanage

Postdoctoral Researchers

9 researchers
Durgadas Cherukaraveedu
Postdoctoral Researcher
Durgadas Cherukaraveedu
Milan Paul
Postdoctoral Researcher
Milan Paul
Narendra Kale
Postdoctoral Researcher
Narendra Kale
Ruma Ghosh
Postdoctoral Researcher
Ruma Ghosh
Dohyun Kim
Postdoctoral Researcher
Dohyun Kim
Maria Paula Avalos
Postdoctoral Researcher
Maria Paula Avalos
Preeti Vyas
Postdoctoral Researcher
Preeti Vyas
Jinhuan Liu
Research Technician
Jinhuan Liu
Spencer Shumway
Research Scientist
Spencer Shumway

Graduate Students

2 students
Kavichandhirakanth Murugesan
PhD Student · Year 3
Kavichandhirakanth Murugesan
PhD Student · Year 1
Easwar Raman

Undergraduate Students

1 student
Undergraduate · Junior
Christine Wu
Lab Alumni
Siva Kambhampati Research Scientist
Elizabeth Nance Postdoctoral Fellow
Fan Zhang Postdoctoral Fellow
Diego Almodiel Graduate Student
Javier Allende Labastida Research Fellow
Research Focus
About

Inside the Kannan Labs

Two decades of dendrimer science, one bench at a time.

Chemistry to clinic

Few labs make the material, test it in disease models, and see it reach patients. Our dendrimers have gone from synthesis to Phase 2 trials, and students here work at every stage of that path.

Validated, then validated again

A targeting result counts once it holds up across models and species. That habit is how the hydroxyl dendrimer platform was confirmed in more than 60 models before it went to the clinic.

Built on partnerships

Our projects run with clinicians and scientists across Wilmer, Kennedy Krieger, and the wider Hopkins campus, and with our spin-out companies. Most papers here have co-authors from more than one department.

Training & growth

New members learn dendrimer synthesis and characterization, in vitro and in vivo testing, and imaging, then take ownership of a project of their own. Presenting at conferences such as CRS is part of the job.

Former lab members now run their own labs, lead R&D teams in industry, and work at our spin-outs.

Open positions →

Selected Work

Prof. Kannan has a rich publication record spanning dendrimer synthesis, drug delivery, and clinical translation. View the complete and up-to-date list on Google Scholar.

View Google Scholar →
2026
Glucose Dendrimer–Ketamine Conjugates Enable Precise and Efficacious Neuromodulation While Preserving Neuronal Network Dynamics
Nano Today, 2026
Delivering ketamine through glucose dendrimers targeted its effect to neurons while leaving normal network activity intact.
2026
Targeted Neuronal Delivery of Creatine Using Glucose Dendrimer for Creatine-Transporter Deficiency and Neonatal Brain Injury
Kale N, Liyanage W, Huang R, Murugesan K, Vyas P, Allende Labastida J, Kannan S, Kannan RM
Regenerative Engineering and Translational Medicine, 2026
Glucose dendrimers carried creatine into neurons, a possible route around the faulty transporter in creatine-transporter deficiency and a candidate therapy for neonatal brain injury.
2025
Efficient Intracellular Delivery of CRISPR-Cas9 Ribonucleoproteins Using Dendrimer Nanoparticles for Robust Genomic Editing
Nano Today, 2025
Dendrimer nanoparticles carried Cas9 ribonucleoproteins into cells efficiently, giving robust gene editing without a viral vector.
2024
Glucose-Dendrimer Based Therapeutic Targeting Hyperexcitable Neurons in Neurological Disorders
Sharma AS, Sah N, Sharma R, Vyas P, Liyanage W, Kannan S*, Kannan RM*
Bioengineering and Translational Medicine, 2024; 9(5):e10655
Glucose dendrimers build up in overactive neurons and largely skip resting ones, offering a way to deliver drugs straight to the brain circuits that drive seizures and other neurological disorders.
2022
Dendrimer Nanotherapy for Severe COVID-19 Attenuates Inflammation & Neurological Injury: Phase 2a Trial
Gusdon AM, Faraday N, Aita JS, et al.
Science Translational Medicine, 2022; 14(654):eabo2652
In hospitalized patients with severe COVID-19, a dendrimer–N-acetylcysteine therapy was well tolerated and lowered markers of inflammation and brain injury compared with placebo.
2021
Systemic Dendrimer Nanotherapies for Targeted Suppression of Choroidal Inflammation in AMD
Kambhampati SP, Bhutto IA, Wu T, Ho K, McLeod SD, Lutty GA*, Kannan RM*
Journal of Controlled Release, 2021; 527–540
Dendrimers given systemically homed to inflamed cells in the back of the eye and suppressed choroidal inflammation in an AMD model, pointing to treatment without eye injections.
2018
Cognitive Impairments from Necrotizing Enterocolitis Prevented by Inhibiting Microglial Activation
Niño DF, Zhou Q, Yamaguchi Y, et al., Kannan RM, Kannan S, Sodhi CP, Hackam DJ
Science Translational Medicine, 2018; 10(471):eaan0237 (Issue Cover)
Necrotizing enterocolitis in newborns can harm the developing brain. Blocking microglial activation with a dendrimer therapy prevented the later cognitive impairment in mice.
2016
Nanoscale Effects in Dendrimer-Mediated Targeting of Neuroinflammation
Nance E, Zhang F, Mishra MK, Zhang Z, Kambhampati SP, Kannan RM*, Kannan S*
Biomaterials, 2016; 101:96–107. PMCID: PMC5379995
Showed how dendrimer size and surface chemistry decide how far they travel through injured brain tissue and which cells take them up.
2014
Dendrimer Brain Uptake & Targeted Therapy in a Large Animal Model of Hypothermic Circulatory Arrest
Mishra MK, Beaty CA, Lesniak WG, Kambhampati SP, Zhang F, et al., Kannan RM*
ACS Nano, 2014; 8(3):2134–2147
In a large-animal model of brain injury after cardiac surgery, dendrimers crossed into the injured brain and reached the affected cells, showing the approach works beyond small animals.
2012
Dendrimer-Based Postnatal Therapy for Neuroinflammation and Cerebral Palsy in a Rabbit Model
Kannan S, Dai H, Navath RS, et al.
Science Translational Medicine, 2012; 4(130):130ra46
A single dendrimer-drug dose after birth markedly improved motor function in a rabbit model of cerebral palsy, the study that established the platform.

From Lab to Patient

The robustness and scalability of our DDCs has enabled significant clinical translation, with two JHU spin-out companies advancing therapies through clinical trials.

Ashvattha Therapeutics
Disease Cell Targeted Precision Medicine · Clinical Stage
Visit Site ↗
The problem

People with wet AMD and diabetic macular edema often need injections into the eye every month or two, for years. Many inflammation-driven diseases of the brain and eye have no treatment that reaches the cells causing the damage.

The approach

Co-founded by Drs. Kannan and Sujatha Kannan, Ashvattha advances clinical-stage nanomedicine that traverses tissue barriers to selectively target activated cells in inflammation, across ophthalmology, neurology, and inflammation.

Where it stands

More than $120 million raised and 6 Phase 1 and 2 Phase 2 trials, all positive. Phase 2 results include a 67% reduction in intravitreal injection need for wet AMD and DME patients.

$120M+
VC Raised
6
Phase 1 Trials
2
Phase 2
All Positive
Samata Therapeutics
CNS-Targeted Cannabinoid & Psychedelic Medicines
Visit Site ↗
The problem

Cannabinoids and psychedelics show promise for epilepsy, pain, and depression, but they act on healthy brain cells too, and those side effects limit how they can be used.

The approach

Co-founded by Drs. Kannan Rangaramanujam, Sujatha Kannan, and Kunal Parikh, Samata builds dendrimer-drug conjugates of cannabinoids and psychedelics that concentrate in the brain cells driving disease.

The goal

Lasting relief for epilepsy, pain, depression, and more, without the systemic side effects of the free drug.

CNS
Focus Area
3+
Therapeutic
Areas
JHU
Co-Founded
at Hopkins

From the Lab

Feature StoryGrit Daily

Destiny, Discovery, and Daring Intuition: Dr. Kannan Rangaramanujam on the Future of Translational Nanomedicine

From a rural village in South India to leading groundbreaking nanomedicine at Johns Hopkins, a story shaped by resilience, intuition, and purpose. His pioneering work has the potential to revolutionize treatments for ocular, neurological, and inflammatory diseases.

Read the story →
Clinical TrialSept 2025

Ashvattha Reports Positive 40-Week Phase 2 Results for Migaldendranib in DME & nAMD

End-of-study results show migaldendranib is safe, well-tolerated, and delivers marked improvements in efficacy with reduced need for intravitreal injections.

Read the release →
MediaWMAR Baltimore

Hopkins Researchers Develop COVID-19 Nanomedicine: Promising Phase 2 Results

Johns Hopkins husband-and-wife researchers develop a dendrimer nanomedicine for severe COVID-19, with stunning Phase 2 results and personal stakes for the Kannan family.

Read the story →
MilestoneApril 2017 · JHU Wilmer

Dedication of the Arnall Patz Distinguished Professorship

Prof. Kannan received the Arnall Patz Distinguished Professorship at the Wilmer Eye Institute, speaking on nanotechnology-based targeted drug delivery for inflammation-driven diseases.

Read more →
Wilmer CentennialJohns Hopkins

Wilmer Celebrates 100 Years: Kannan Lab's Precision Nanomedicine Featured

Phase IIa results showing 67% reduction in intravitreal injection need highlighted in Wilmer's centennial. A subcutaneous treatment with a systemic bilateral effect, a "stunning proof of concept."

Read more →

Work With Us

Prospective students, postdocs, visiting scientists, and industry collaborators are encouraged to reach out.

Prospective students & postdocs

We take PhD rotation students, postdocs, visiting scholars, and undergraduates. Send your CV and a few lines on which of our platforms you'd want to work on.

Email Prof. Kannan

Partnerships

Clinicians, academic groups, and companies with a disease where getting the drug to the right cell is the bottleneck. We're glad to talk about dendrimer approaches.

Start the conversation

Get in Touch

Please include your CV and a brief statement of research interest when reaching out.

Address400 N Broadway
Baltimore, Maryland 21231-1104
Johns Hopkins University
Phone+1 (443) 287-7921
InstitutionCenter for Nanomedicine
Wilmer Eye Institute · JHU School of Medicine

Prospective Lab Members

Fill out the form and your message will open in your email client addressed to Prof. Kannan.

→ Clicking Send will open your email client pre-filled to krangar1@jhmi.edu